Septic arthritis is a medical emergency characterized by microbial infection of the joint space, leading to acute inflammation, rapid joint destruction, and potential systemic complications. Children and immunocompromised patients, particularly those with sickle cell disease, are at heightened risk for severe manifestations due to impaired immune function and increased susceptibility to invasive bacterial infections. The incidence of pediatric septic arthritis ranges from 2 to 7 cases per 100,000 children annually in developed countries, with higher prevalence reported in regions with limited healthcare access. Large joints such as the knees, hips, and elbows are most commonly affected, and delayed diagnosis or treatment can result in permanent joint dysfunction or life-threatening sequelae. The spectrum of causative organisms varies with age, comorbidities, geographic region, and history of trauma or invasive procedures. Accurate and timely microbiological diagnosis is essential for effective management, guiding the selection of appropriate antimicrobial therapy and optimizing clinical outcomes. Early identification of the offending pathogen not only facilitates targeted treatment but also helps prevent the progression of infection and minimizes the risk of irreversible joint damage. In patients with sickle cell disease, where infection risk is elevated and immune responses are altered, microbiological evaluation becomes a cornerstone of management to reduce morbidity and improve prognosis. This review highlights the clinical significance of early microbiological diagnosis in pediatric septic arthritis, with emphasis on bilateral involvement in patients with sickle cell disease. It underscores the importance of prompt recognition, targeted antimicrobial therapy, and supportive care in mitigating joint damage and systemic complications, particularly in resource-limited settings where both disease burden and access to advanced diagnostic tools may be constrained.